182 related articles for article (PubMed ID: 19177354)
1. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.
Lountos GT; Tropea JE; Zhang D; Jobson AG; Pommier Y; Shoemaker RH; Waugh DS
Protein Sci; 2009 Jan; 18(1):92-100. PubMed ID: 19177354
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase.
Jobson AG; Cardellina JH; Scudiero D; Kondapaka S; Zhang H; Kim H; Shoemaker R; Pommier Y
Mol Pharmacol; 2007 Oct; 72(4):876-84. PubMed ID: 17616632
[TBL] [Abstract][Full Text] [Related]
3. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].
Jobson AG; Lountos GT; Lorenzi PL; Llamas J; Connelly J; Cerna D; Tropea JE; Onda A; Zoppoli G; Kondapaka S; Zhang G; Caplen NJ; Cardellina JH; Yoo SS; Monks A; Self C; Waugh DS; Shoemaker RH; Pommier Y
J Pharmacol Exp Ther; 2009 Dec; 331(3):816-26. PubMed ID: 19741151
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
J Struct Biol; 2011 Dec; 176(3):292-301. PubMed ID: 21963792
[TBL] [Abstract][Full Text] [Related]
5. X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket.
Lountos GT; Jobson AG; Tropea JE; Self CR; Zhang G; Pommier Y; Shoemaker RH; Waugh DS
FEBS Lett; 2011 Oct; 585(20):3245-9. PubMed ID: 21907711
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.
Saleem RS; Lansdell TA; Tepe JJ
Bioorg Med Chem; 2012 Feb; 20(4):1475-81. PubMed ID: 22285028
[TBL] [Abstract][Full Text] [Related]
7. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange.
Oliver AW; Paul A; Boxall KJ; Barrie SE; Aherne GW; Garrett MD; Mittnacht S; Pearl LH
EMBO J; 2006 Jul; 25(13):3179-90. PubMed ID: 16794575
[TBL] [Abstract][Full Text] [Related]
8. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
Anderson VE; Walton MI; Eve PD; Boxall KJ; Antoni L; Caldwell JJ; Aherne W; Pearl LH; Oliver AW; Collins I; Garrett MD
Cancer Res; 2011 Jan; 71(2):463-72. PubMed ID: 21239475
[TBL] [Abstract][Full Text] [Related]
9. Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2.
Silva-Santisteban MC; Westwood IM; Boxall K; Brown N; Peacock S; McAndrew C; Barrie E; Richards M; Mirza A; Oliver AW; Burke R; Hoelder S; Jones K; Aherne GW; Blagg J; Collins I; Garrett MD; van Montfort RL
PLoS One; 2013; 8(6):e65689. PubMed ID: 23776527
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine.
Curman D; Cinel B; Williams DE; Rundle N; Block WD; Goodarzi AA; Hutchins JR; Clarke PR; Zhou BB; Lees-Miller SP; Andersen RJ; Roberge M
J Biol Chem; 2001 May; 276(21):17914-9. PubMed ID: 11279124
[TBL] [Abstract][Full Text] [Related]
11. Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.
Nguyen TN; Saleem RS; Luderer MJ; Hovde S; Henry RW; Tepe JJ
ACS Chem Biol; 2012 Jan; 7(1):172-84. PubMed ID: 22004065
[TBL] [Abstract][Full Text] [Related]
12. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale.
Pommier Y; Sordet O; Rao VA; Zhang H; Kohn KW
Curr Pharm Des; 2005; 11(22):2855-72. PubMed ID: 16101442
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles.
Arienti KL; Brunmark A; Axe FU; McClure K; Lee A; Blevitt J; Neff DK; Huang L; Crawford S; Pandit CR; Karlsson L; Breitenbucher JG
J Med Chem; 2005 Mar; 48(6):1873-85. PubMed ID: 15771432
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2.
Caldwell JJ; Welsh EJ; Matijssen C; Anderson VE; Antoni L; Boxall K; Urban F; Hayes A; Raynaud FI; Rigoreau LJ; Raynham T; Aherne GW; Pearl LH; Oliver AW; Garrett MD; Collins I
J Med Chem; 2011 Jan; 54(2):580-90. PubMed ID: 21186793
[TBL] [Abstract][Full Text] [Related]
16. Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification.
Foloppe N; Fisher LM; Francis G; Howes R; Kierstan P; Potter A
Bioorg Med Chem; 2006 Mar; 14(6):1792-804. PubMed ID: 16289938
[TBL] [Abstract][Full Text] [Related]
17. Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains.
Ng CP; Lee HC; Ho CW; Arooz T; Siu WY; Lau A; Poon RY
J Biol Chem; 2004 Mar; 279(10):8808-19. PubMed ID: 14681223
[TBL] [Abstract][Full Text] [Related]
18. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2.
Zhang WH; Poh A; Fanous AA; Eastman A
Cell Cycle; 2008 Jun; 7(11):1668-77. PubMed ID: 18469532
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1.
Yoda A; Xu XZ; Onishi N; Toyoshima K; Fujimoto H; Kato N; Oishi I; Kondo T; Minami Y
J Biol Chem; 2006 Aug; 281(34):24847-62. PubMed ID: 16798742
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2.
Li J; Williams BL; Haire LF; Goldberg M; Wilker E; Durocher D; Yaffe MB; Jackson SP; Smerdon SJ
Mol Cell; 2002 May; 9(5):1045-54. PubMed ID: 12049740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
